👤 Lijuan Chen

🔍 Search 📋 Browse 🏷️ Tags ❤️ Favourites ➕ Add 🧪 BiometalDB 🧬 Extraction
2981
Articles
1996
Name variants
Also published as: Wen-Chau Chen, Jingzhao Chen, Dexi Chen, Haifeng Chen, Chung-Jen Chen, Bo-Jun Chen, Gao-Feng Chen, Changyan Chen, Weiwei Chen, Fenghua Chen, Xiaojiang S Chen, Xiu-Juan Chen, Jung-Sheng Chen, Xiao-Ying Chen, Chong Chen, Junyang Chen, YiPing Chen, Xiaohan Chen, Li-Zhen Chen, Jiujiu Chen, Shin-Wen Chen, Guangping Chen, Dapeng Chen, Ximei Chen, Renwei Chen, Jianfei Chen, Yulu Chen, Yu-Chi Chen, Jia-De Chen, Rongfang Chen, She Chen, Zetian Chen, Tianran Chen, Emily Chen, Baoxiang Chen, Ya-Chun Chen, Dongxue Chen, Wei-xian Chen, Danmei Chen, Ceshi Chen, Junling Chen, Xia Chen, Daoyuan Chen, Yongbin Chen, Chi-Yu Chen, Dian Chen, Xiuxiu Chen, Bo-Fang Chen, Fangyuan Chen, Jin-An Chen, Xiaojuan Chen, Zhuohui Chen, Junqi Chen, Lina Chen, Fangfang Chen, Hanwen Chen, Yilei Chen, Po-Han Chen, Xiaoxiang Chen, Jimei Chen, Guochong Chen, Yanyun Chen, Yifei Chen, Cheng-Yu Chen, Zi-Jiang Chen, Jiayuan Chen, Miaoran Chen, Junshi Chen, Yu-Ying Chen, Pengxiang Chen, Hui-Ru Chen, Yupeng Chen, Ida Y-D Chen, Xiaofeng Chen, Qiqi Chen, Shengnan Chen, Mao-Yuan Chen, Lizhu Chen, Weichan Chen, Xiang-Bin Chen, Hanxi Chen, Sulian Chen, Zoe Chen, Minghong Chen, Chi Chen, Yananlan Chen, Yanzhu Chen, Shiyi Chen, Ze-Xu Chen, Zhiheng Chen, Jia-Mei Chen, Shuqin Chen, Yi-Hau Chen, Danni Chen, Donglong Chen, Xiaomeng Chen, Yidong Chen, Keyu Chen, Hao Chen, Junmin Chen, Wenlong Chen, Yufei Chen, Wanbiao Chen, Mo Chen, Youjia Chen, Xin-Jie Chen, Lanlan Chen, Huapu Chen, Shuaiyin Chen, Jing-Hsien Chen, Hengsheng Chen, Bing-Bing Chen, Fa-Xi Chen, Zhiqiang Chen, Ming-Huang Chen, Liangkai Chen, Li-Jhen Chen, Zhi-Hao Chen, Yinzhu Chen, Guanghong Chen, Gaozhi Chen, Jiakang Chen, Yongke Chen, Guangquan Chen, Li-Hsien Chen, Yiduo Chen, Zongnan Chen, Jing Chen, Meilan Chen, Jin-Shuen Chen, Huanxiong Chen, Yann-Jang Chen, Guozhong Chen, Yu-Bing Chen, Xiaobin Chen, Catherine Qing Chen, Youhu Chen, Hui Mei Chen, L F Chen, Haiyang Chen, Ruilin Chen, Peng Chen, Kailang Chen, Chao Chen, Suipeng Chen, Zemin Chen, Jianlin Chen, Shang-Chih Chen, Yen-Hsieh Chen, Jia-Lin Chen, Chaojin Chen, Minglang Chen, Xiatian Chen, Zeyu Chen, Kang Chen, Mei-Chi Chen, Jihai Chen, Pei Chen, Defang Chen, Zhao Chen, Tianrui Chen, Tingtao Chen, Caressa Chen, Jiwei Chen, Xuerong Chen, Yizhi Chen, XueShu Chen, Mingyue Chen, Huichao Chen, Chun-Chi Chen, Xiaomin Chen, Hetian Chen, Yuxing Chen, Jie-Hua Chen, Chuck T Chen, Yuanjia Chen, Hong Chen, Jianxiong Chen, S Chen, D M Chen, Jiao-Jiao Chen, Gongbo Chen, Xufeng Chen, Xiao-Jun Chen, Harn-Shen Chen, Qiu Jing Chen, Tai-Heng Chen, Pei-Lung Chen, Kaifu Chen, Huang-Pin Chen, Tse-Wei Chen, Yanrong Chen, Xianfeng Chen, Chung-Yung Chen, Yuelei Chen, Qili Chen, Guanren Chen, TsungYen Chen, Yu-Si Chen, Junsheng Chen, Min-Jie Chen, Xin-Ming Chen, Jiabing Chen, Sili Chen, Qinying Chen, Yue Chen, Lin Chen, Xiaoli Chen, Zhuo Chen, Aoshuang Chen, Junyu Chen, Chunji Chen, Yian Chen, Shanchun Chen, Shuen-Ei Chen, Canrong Chen, Shih-Jen Chen, Yaowu Chen, Han Chen, Yih-Chieh Chen, Wei-Cong Chen, Yanfen Chen, Tao Chen, Huangtao Chen, Jingyi Chen, Sheng Chen, Jing-Wen Chen, Gao Chen, Lei-Lei Chen, Kecai Chen, Yao-Shen Chen, Haiyu Chen, W Chen, Xiaona Chen, Cheng-Sheng Chen, X R Chen, Shuangfeng Chen, Jingyuan Chen, Xinyuan Chen, Huanhuan Chen, Mengling Chen, Liang-Kung Chen, Ming-Huei Chen, Hongshan Chen, Cuncun Chen, Qingchao Chen, Yanzi Chen, Lingli Chen, Shiqian Chen, Liangwan Chen, Lexia Chen, Wei-Ting Chen, Zhencong Chen, Tzy-Yen Chen, Mingcong Chen, Honglei Chen, Yuyan Chen, Huachen Chen, Yu Chen, Li-Juan Chen, Aozhou Chen, Xinlin Chen, Wai Chen, Dake Chen, Bo-Sheng Chen, Meilin Chen, Kequan Chen, Hong Yang Chen, Yan Chen, Bowei Chen, Silian Chen, Jian Chen, Yongmei Chen, Ling Chen, Jinbo Chen, Yingxi Chen, Ge Chen, Max Jl Chen, C Z Chen, Weitao Chen, Xiaole L Chen, Yonglu Chen, Shih-Pin Chen, Jiani Chen, Huiru Chen, San-Yuan Chen, Bing Chen, Xiao-ping Chen, Feiyue Chen, Shuchun Chen, Zhaolin Chen, Qianxue Chen, Xiaoyang Chen, Bowang Chen, Yinghui Chen, Ting-Ting Chen, Xiao-Yang Chen, Chi-Yuan Chen, Zhi-zhe Chen, Ting-Tao Chen, Xiaoyun Chen, Min-Hsuan Chen, Kuan-Ting Chen, Yongheng Chen, Wenhao Chen, Shengyu Chen, Kai Chen, Yueh-Peng Chen, Guangju Chen, Minghua Chen, Hong-Sheng Chen, Qingmei Chen, Song-Mei Chen, Limei Chen, Yuqi Chen, Yuyang Chen, Yang-Ching Chen, Yu-Gen Chen, Peizhan Chen, Rucheng Chen, Jin-Xia Chen, Szu-Chieh Chen, Xiaojun Chen, Jialing Chen, Heni Chen, Yi Feng Chen, Sen Chen, Alice Ye A Chen, Wen Chen, Han-Chun Chen, Dawei Chen, Fangli Chen, Ai-Qun Chen, Zhaojun Chen, Gong Chen, Yishan Chen, Zhijing Chen, Qiuxuan Chen, Miao-Der Chen, Fengwu Chen, Weijie Chen, Weixin Chen, Mei-Ling Chen, Hung-Po Chen, Rui-Pei Chen, Nian-Ping Chen, Tielin Chen, Canyu Chen, Xiaotao Chen, Nan Chen, C Chen, Juanjuan Chen, Xinan Chen, Jiaping Chen, Xiao-Lin Chen, Jianping Chen, Yayun Chen, Le Qi Chen, Jen-Sue Chen, Mechi Chen, Miao-Yu Chen, Zhou Chen, Szu-Han Chen, Zhen Bouman Chen, Baihua Chen, Qingao Chen, Shao-Ke Chen, Feng Chen, Jiawen Chen, Lianmin Chen, Sifeng Chen, Mengxia Chen, Xueli Chen, Can Chen, Yibo Chen, Zinan Chen, Lei-Chin Chen, Carol Chen, Yanlin Chen, Zihang Chen, Zaozao Chen, Haiqin Chen, Lu Hua Chen, Zhiyuan Chen, Meiyu Chen, Du-Qun Chen, Keying Chen, Naifei Chen, Peixian Chen, Jin-Ran Chen, Yijun Chen, Yulin Chen, Fumei Chen, Zhanfei Chen, Zhe-Yu Chen, Xin-Qi Chen, Valerie Chen, Ru Chen, Mengqing Chen, Runsheng Chen, Tong Chen, Tan-Zhou Chen, Suet Nee Chen, Cuicui Chen, Yifan Chen, Tian Chen, XiangFan Chen, Lingyi Chen, Hsiao-Yun Chen, Kenneth L Chen, Ni Chen, Huishan Chen, Fang-Yu Chen, Ken Chen, Yongshen Chen, Qiong Chen, Mingfeng Chen, Shoudeng Chen, Qiao Chen, Qian Chen, Yuebing Chen, Xuehua Chen, Chang-Lan Chen, Min-Hu Chen, Hongbin Chen, Jingming Chen, Qing Chen, Yu-Fan Chen, Hao-Zhu Chen, Yunjia Chen, Zhongjian Chen, Mingyi Chen, Qianping Chen, Huaxin Chen, Dong-Mei Chen, Peize Chen, Leijie Chen, Ming-Yu Chen, Jiaxuan Chen, Xiao-chun Chen, Wei-Min Chen, Ruisen Chen, Xuanwei Chen, Guiquan Chen, Minyan Chen, Feng-Ling Chen, Yili Chen, Alvin Chen, Xiaodong Chen, Bohong Chen, Chih-Ping Chen, Xuanjing Chen, Shuhui Chen, Ming-Hong Chen, Tzu-Yu Chen, Brian Chen, Bowen Chen, Kai-En Chen, Szu-Chia Chen, Guangchun Chen, Fang Chen, Chuyu Chen, Haotian Chen, Xiaoting Chen, Shaoliang Chen, Chun-Houh Chen, Shali Chen, Yu-Cheng Chen, Zhijun Chen, B Chen, Yuan Chen, Zhanglin Chen, Chaoran Chen, Xing-Long Chen, Zhinan Chen, Yu-Hui Chen, Yuquan Chen, Andrew Chen, Fengming Chen, Guangyong Chen, Jun Chen, Wenshuo Chen, Yi-Guang Chen, Jing-Yuan Chen, Kuangyang Chen, Mingyang Chen, Shaofei Chen, Weicong Chen, Gonghai Chen, Di-Long Chen, Limin Chen, Jishun Chen, Yunfei Chen, Caihong Chen, Tongsheng Chen, Ligang Chen, Wenqin Chen, Shiyu Chen, Xiaoyong Chen, Christina Y Chen, Yushan Chen, Ginny I Chen, Guo-Jun Chen, Xianzhen Chen, Wanling Chen, Kuan-Jen Chen, Maorong Chen, Kaijian Chen, Erqu Chen, Shen Chen, Quan Chen, Zian Chen, Yi-Lin Chen, Juei-Suei Chen, Yi-Ting Chen, Huaiyong Chen, Minjian Chen, Qianzhi Chen, Jiahao Chen, Xikun Chen, Juan-Juan Chen, Xiaobo Chen, Tianzhen Chen, Ziming Chen, Qianbo Chen, Jindong Chen, Jiu-Chiuan Chen, Yinwei Chen, Carl Pc Chen, Li-Hsin Chen, Jenny Chen, Ruoyan Chen, Yanqiu Chen, Yen-Fu Chen, Haiyan Chen, Zhebin Chen, Si Chen, Jian-Qiao Chen, Yang-Yang Chen, Ningning Chen, Zhifeng Chen, Zhenyi Chen, Hangang Chen, Zihe Chen, Mengdi Chen, Zhichuan Chen, Xu Chen, Huixi Chen, Weitian Chen, Bao-Sheng Chen, Tien-Hsing Chen, Junchen Chen, Yan-yan Chen, Xiangning Chen, Sijia Chen, Xinyan Chen, Kuan-Yu Chen, Qunxiang Chen, Guangliang Chen, Bing-Huei Chen, Fei Xavier Chen, Zhangcheng Chen, Qianming Chen, Xianze Chen, Yanhua Chen, Qinghao Chen, Yanting Chen, Sijuan Chen, Chen-Mei Chen, Qiankun Chen, Jianan Chen, Rong Chen, Xiankai Chen, Kaina Chen, Gui-Hai Chen, Y-D Ida Chen, Quanjiao Chen, Shuang Chen, Lichang Chen, Xinyi Chen, Yong-Jun Chen, Zhaoli Chen, Chunnuan Chen, Jui-Chang Chen, Zhiang Chen, Weirui Chen, Zhenguo Chen, Jennifer F Chen, Zhiguo Chen, Kunmei Chen, Huan-Xin Chen, Mengyan Chen, Dongrong Chen, Siyue Chen, Xianyue Chen, Chien-Lun Chen, YiChung Chen, Guang Chen, Quanwei Chen, Zongming E Chen, Ting-Huan Chen, Michael C Chen, Jinli Chen, Beth L Chen, Yuh-Lien Chen, Peihong Chen, Qiaoling Chen, Jiale Chen, Shufeng Chen, Xiaowan Chen, Xian-Kai Chen, Ling-Yan Chen, Yen-Ling Chen, Guiying Chen, Guangyi Chen, Yuling Chen, Xiangqiu Chen, Haiquan Chen, Cuie Chen, Gui-Lai Chen, R Chen, Heng-Yu Chen, Yongxun Chen, Fuxiang Chen, Mingmei Chen, Hua-Pu Chen, Yulong Chen, Zhitao Chen, Guohua Chen, Cheng-Yi Chen, Hongxu Chen, Yuanhao Chen, Qichen Chen, Hualin Chen, Guo-Rong Chen, Rongsheng Chen, Xuesong Chen, Wei-Fei Chen, Bao-Bao Chen, Anqi Chen, Yi-Han Chen, Ying-Jung Chen, Jinhuang Chen, Guochao Chen, Lei Chen, S N Chen, Songfeng Chen, Chenyang Chen, Xing Chen, Letian Chen, Meng Xuan Chen, Xiang-Mei Chen, Xiaoyan Chen, Yi-Heng Chen, D F Chen, Bang Chen, Jiaxu Chen, Wei Chen, Sihui Chen, Shu-Hua Chen, I-M Chen, Xuxin Chen, Zhangxin Chen, Jin Chen, Yin-Huai Chen, Wuyan Chen, Bingqing Chen, Bao-Fu Chen, Zhen-Hua Chen, Dan Chen, Zhe-Sheng Chen, Ranyun Chen, Wanyin Chen, Xueyan Chen, Xiaoyu Chen, Tai-Tzung Chen, Xiaofang Chen, Yongxing Chen, Yanghui Chen, Hekai Chen, Yuanwei Chen, Liang Chen, Hui-Jye Chen, Chengchun Chen, Han-Bin Chen, Shuaijie Chen, Yibing Chen, Kehui Chen, Shuhai Chen, Xueling Chen, Ying-Jie Chen, Qingxing Chen, Fang-Zhi Chen, Mei-Hua Chen, Yutong Chen, Lixian Chen, Alex Chen, Qiuhong Chen, Qiuxia Chen, Liping Chen, Hou-Tsung Chen, Zhanghua Chen, Chun-Fa Chen, Chian-Feng Chen, Benjamin P C Chen, Yewei Chen, Mu-Hong Chen, Jianshan Chen, Xiaguang Chen, Meiling Chen, Heng Chen, Ying-Hsiang Chen, Longyun Chen, Dengpeng Chen, Jichong Chen, Shixuan Chen, Liaobin Chen, Everett H Chen, ZhuoYu Chen, Qihui Chen, Zhiyong Chen, Nuan Chen, Hongmei Chen, Guiqian Chen, Yan Q Chen, Fengling Chen, Hung-Chang Chen, Zhenghong Chen, Chengsheng Chen, Hegang Chen, Huei-Yan Chen, Liutao Chen, Meng-Lin Chen, Xi Chen, Qing-Juan Chen, Linna Chen, Xiaojing Chen, Lang Chen, Gengsheng Chen, Fengrong Chen, Weilun Chen, Shi Chen, Wan-Yi Chen, On Chen, Yufeng Chen, Benjamin Chen, Hui-Zhao Chen, Bo-Rui Chen, Kangyong Chen, Ruixiang Chen, Weiyong Chen, Ning-Hung Chen, Meng-Ping Chen, Huimei Chen, Ying Chen, Kang-Hua Chen, Pei-zhan Chen, Liujun Chen, Hanqing Chen, Chengchuan Chen, Guojun Chen, Yongfa Chen, Li Chen, Mingling Chen, Jacinda Chen, Jinlun Chen, Kun Chen, Yi Chen, Chiung Mei Chen, Shaotao Chen, Tianhong Chen, Chanjuan Chen, Yuhao Chen, Huizhi Chen, Chung-Hsing Chen, Qiuchi Chen, Haoting Chen, Luzhu Chen, Huanhua Chen, Long Chen, Jiang-hua Chen, Kai-Yang Chen, Jing-Zhou Chen, Yong-Syuan Chen, Lifang Chen, Ruonan Chen, Meimei Chen, Qingchuan Chen, Liugui Chen, Shaokun Chen, Yi-Yung Chen, Jintian Chen, Xuhui Chen, Dongyan Chen, Huei-Rong Chen, Xianmei Chen, Jinyan Chen, Yuxi Chen, Qingqing Chen, Weibo Chen, Qiwei Chen, Mingxia Chen, Hongmin Chen, Jiahui Chen, Yen-Jen Chen, Zihan Chen, Guozhou Chen, Fei Chen, Zhiting Chen, Denghui Chen, Gary Chen, Hongli Chen, Jack Chen, Zhigang Chen, Lie Chen, Siyuan Chen, Haojie Chen, Qing-Wei Chen, Maochong Chen, Mei-Jie Chen, Haining Chen, Xing-Zhen Chen, Weiqing Chen, Huanchun Chen, C-Y Chen, Tzu-An Chen, Jen-Hau Chen, Xiaojie Chen, Dongquan Chen, Gao B Chen, Daijie Chen, Zixi Chen, Lingfeng Chen, Jiayi Chen, Zan Chen, Shuming Chen, Mei-Hsiu Chen, Xueqin Chen, Huan Chen, Xiaoqing Chen, Hui-Xiong Chen, Ruoying Chen, Deying Chen, Huixian Chen, Zhezhe Chen, Lu Chen, Xiaolong Chen, Si-Yue Chen, Xinwei Chen, Wentao Chen, Yucheng Chen, Jiajing Chen, Allen Menglin Chen, Chixiang Chen, Shiqun Chen, Wenwu Chen, Chin-Chuan Chen, Ningbo Chen, Hsin-Hung Chen, Shenglan Chen, Jia-Feng Chen, Changya Chen, ZhaoHui Chen, Guo Chen, Juhai Chen, Xiao-Quan Chen, Cuimin Chen, Yongshuo Chen, Sai Chen, Fengyang Chen, Siteng Chen, Hualan Chen, Lian Chen, Yuan-Hua Chen, Minjie Chen, Shiyan Chen, Z Chen, Zhengzhi Chen, Jonathan Chen, H Chen, You-Yue Chen, Shu-Gang Chen, Hsuan-Yu Chen, Hongyue Chen, Weiyi Chen, Jiaqi Chen, Chengde Chen, Shufang Chen, Ze-Hui Chen, Xiuping Chen, Zhuojia Chen, Zhouji Chen, Lidian Chen, Yilan Chen, Kuan-Ling Chen, Alon Chen, Zi-Yue Chen, Hongmou Chen, Fang-Zhou Chen, Jianzhou Chen, Wenbiao Chen, Yujie Chen, Zhijian Chen, Zhouqing Chen, Xiuhui Chen, Qingguang Chen, Hanbei Chen, Qianyu Chen, Mengping Chen, Yongqi Chen, Sheng-Yi Chen, Siqi Chen, Yelin Chen, Shirui Chen, Yuan-Tsong Chen, Dongyin Chen, Lingxue Chen, Long-Jiang Chen, Yunshun Chen, Yahong Chen, Yaosheng Chen, Zhonghua Chen, Jingyao Chen, Pei-Yin Chen, Fusheng Chen, Xiaokai Chen, Shuting Chen, Miao-Hsueh Chen, Y-D I Chen, Zijie Chen, Haozhu Chen, Haodong Chen, Xiong Chen, Wenxi Chen, Feng-Jung Chen, Shangwu Chen, Zhiping Chen, Zhang-Yuan Chen, Wentong Chen, Ou Chen, Ruiming Chen, Xiyu Chen, Shuqiu Chen, Xiaoling Chen, Ruimin Chen, Hsiao-Wang Chen, Dongli Chen, Haibo Chen, Yiyun Chen, Luming Chen, Wenting Chen, Chongyang Chen, Qingqiu Chen, Wen-Pin Chen, Yuhui Chen, Lingxia Chen, Jun-Long Chen, Xingyu Chen, Haotai Chen, Bang-dang Chen, Qiuwen Chen, Rui Chen, K C Chen, Zhixuan Chen, Gaoyu Chen, Yitong Chen, Tzu-Ju Chen, Jingqing Chen, Huiqun Chen, Runsen Chen, Michelle Chen, Hanyong Chen, Xiaolin Chen, Ke Chen, Yangchao Chen, Y D I Chen, Jinghua Chen, Jia Wei Chen, Man-Hua Chen, H T Chen, Zheyi Chen, Lihong Chen, Guangyao Chen, Rujun Chen, Ming-Fong Chen, Haiyun Chen, Dexiong Chen, Huiqin Chen, Ching Kit Chen, En-Qiang Chen, Wanjia Chen, Xiangliu Chen, Meiting Chen, Szu-Chi Chen, Yii-der Ida Chen, Jian-Hua Chen, Yanjie Chen, Yingying Chen, Paul Chih-Hsueh Chen, Si-Ru Chen, Mingxing Chen, Rui-Zhen Chen, Changjie Chen, Qu Chen, Yintong Chen, Jingde Chen, Mao Chen, Xinghai Chen, Mei-Chih Chen, Xueqing Chen, Chun-An Chen, Cheng Chen, Ruijing Chen, Huayu Chen, Yunqin Chen, Yan-Gui Chen, Ruibing Chen, Size Chen, Qi-An Chen, Yuan-Zhen Chen, J Chen, Heye Chen, T Chen, Junpeng Chen, Tan-Huan Chen, Shuaijun Chen, Hao Yu Chen, Fahui Chen, Lan Chen, Dong-Yi Chen, Xianqiang Chen, Shi-Sheng Chen, Qiao-Yi Chen, Pei-Chen Chen, Xueying Chen, Yi-Wen Chen, Guohong Chen, Zhiwei Chen, Zuolong Chen, Erfei Chen, Yuqing Chen, Zhenyue Chen, Qiongyun Chen, Jianghua Chen, Yingji Chen, Xiuli Chen, Xiaowei Chen, Hengyu Chen, Sheng-Xi Chen, Haiyi Chen, Shao-Peng Chen, Yi-Ru Chen, Zhaoran Chen, Xiuyan Chen, Jinsong Chen, Sunny Chen, Xiaolan Chen, S-D Chen, Ruofan Chen, Qiujing Chen, Yun Chen, Wei-Cheng Chen, Chun-Wei Chen, Liechun Chen, Lulu Chen, Hsiu-Wen Chen, Yanping Chen, Jiayao Chen, Xuejiao Chen, Guan-Wei Chen, Yusi Chen, Yijiang Chen, Chi-Hua Chen, Qixian Chen, Ziqing Chen, Peiyou Chen, Chunhai Chen, Zheren Chen, Qiuyun Chen, Xiaorong Chen, Chaoqun Chen, Dan-Dan Chen, Xuechun Chen, Yafang Chen, Mystie X Chen, Jina Chen, Wei-Kai Chen, Yule Chen, Bo Chen, Kaili Chen, Junqin Chen, Jia Min Chen, Chen Chen, Guoliang Chen, Xiaonan Chen, Guangjie Chen, Xiao Chen, Jeanne Chen, Danyang Chen, Minjiang Chen, Jiyuan Chen, Zheng-Zhen Chen, Shou-Tung Chen, Ouyang Chen, Xiu Chen, H Q Chen, Peiyu Chen, Yuh-Min Chen, Youmeng Chen, Shuoni Chen, Peiqin Chen, Xinji Chen, Chih-Ta Chen, Shang-Hung Chen, Robert Chen, Suet N Chen, Yun-Tzu Chen, Suming Chen, Ye Chen, Yao Chen, Yi-Fei Chen, Ruixue Chen, Tianhang Chen, Suning Chen, Jingnan Chen, Xiaohong Chen, Kun-Chieh Chen, Tuantuan Chen, Mei Chen, He-Ping Chen, Zhi Bin Chen, Yuewu Chen, Mengying Chen, Po-See Chen, Xue Chen, Jian-Jun Chen, Xiyao Chen, Jeremy J W Chen, Jiemei Chen, Daiwen Chen, Christina Yingxian Chen, Qinian Chen, Chih-Wei Chen, Wensheng Chen, Yingcong Chen, Zhishi Chen, Duo Chen, Jiansu Chen, Keping Chen, Min Chen, Yi-Hui Chen, Yun-Ju Chen, Gaoyang Chen, Renjin Chen, Kui Chen, Shuai-Ming Chen, Hui-Fen Chen, Zi-Yun Chen, Shao-Yu Chen, Meiyang Chen, Jiahua Chen, Zongyou Chen, Yen-Rong Chen, Huaping Chen, Yu-Xin Chen, Bohe Chen, Kehua Chen, Zilin Chen, Zhang-Liang Chen, Ziqi Chen, Yinglian Chen, Hui-Wen Chen, Peipei Chen, Baolin Chen, Zugen Chen, Kangzhen Chen, Yanhan Chen, Sung-Fang Chen, Zheping Chen, Zixuan Chen, Jiajia Chen, Yuanjian Chen, Lili Chen, Xiangli Chen, Ban Chen, Yuewen Chen, X Chen, Yan-Qiong Chen, Chider Chen, Yung-Hsiang Chen, Hanlin Chen, Xiangjun Chen, Haibing Chen, Le Chen, Xuan Chen, Xue-Ying Chen, Zexiao Chen, Chen-Yu Chen, Zhe-Ling Chen, Fan Chen, Hsin-Yi Chen, Feilong Chen, Zilong Chen, Yi-Jen Chen, Zhiyun Chen, Ning Chen, Wenxu Chen, Chuanbing Chen, Yaxi Chen, Yi-Hong Chen, Eleanor Y Chen, Yuexin Chen, Kexin Chen, Shoujun Chen, Yen-Ju Chen, Yu-Chuan Chen, Yen-Teen Chen, Bao-Ying Chen, Xiaopeng Chen, Danli Chen, Katharine Y Chen, Jingli Chen, Qianyi Chen, Zihua Chen, Ya-xi Chen, Xuanxu Chen, Chung-Hung Chen, Yajie Chen, Cindi Chen, Hua Chen, Shuliang Chen, Elizabeth H Chen, Gen-Der Chen, Bingyu Chen, Keyang Chen, Siyu S Chen, Xinpu Chen, Yau-Hung Chen, Hsueh-Fen Chen, Han-Hsiang Chen, Wei Ning Chen, Guopu Chen, Zhujun Chen, Yurong Chen, Yuxian Chen, Wanjun Chen, Qiu-Jing Chen, Qifang Chen, Yuhan Chen, Jingshen Chen, Zhongliang Chen, Ching-Hsuan Chen, Zhaoyao Chen, Yongning Chen, Marcus Y Chen, Ping Chen, Junfei Chen, Yung-Wu Chen, Xueting Chen, Yingchun Chen, Wan-Yan Chen, Yuxin Chen, Yisheng Chen, Chun-Yuan Chen, Yulian Chen, Yan-Jun Chen, Guoxun Chen, Ding Chen, Yu-Fen Chen, Jason A Chen, Shuyi Chen, Cuilan Chen, Ruijuan Chen, Kevin Chen, Xuanmao Chen, Shen-Ming Chen, Ya-Nan Chen, Sean Chen, Zhaowei Chen, Xixi Chen, Yu-Chia Chen, Xuemin Chen, Binlong Chen, Weina Chen, Xuemei Chen, Di Chen, P P Chen, Yubin Chen, Chunhua Chen, Li-Chieh Chen, Ping-Chung Chen, Zhihao Chen, Xinyang Chen, Chan Chen, Yan Jie Chen, Shi-Qing Chen, Ivy Xiaoying Chen, Ying-Cheng Chen, Jia-Shun Chen, Shao-Wei Chen, Aiping Chen, Dexiang Chen, Qianfen Chen, Hongyu Chen, Wei-Kung Chen, Danlei Chen, Hongen Chen, Shipeng Chen, Jake Y Chen, Dongsheng Chen, Chien-Ting Chen, Shouzhen Chen, Hehe Chen, Yu-Tung Chen, Yilin Chen, Joy J Chen, Zhong Chen, Zhenfeng Chen, Zhongzhu Chen, Feiyang Chen, Xingxing Chen, Keyan Chen, Huimin Chen, Guanyu Chen, D. Chen, Dianke Chen, Zhigeng Chen, Sien-Tsong Chen, Yii-Der Chen, Chi-Yun Chen, Beidong Chen, Wu-Xian Chen, Zhihang Chen, Yuanqi Chen, Jianhua Chen, Xian Chen, Xiangding Chen, Jingteng Chen, Shuaiyu Chen, Xue-Mei Chen, Yu-Han Chen, Hongqiao Chen, Weili Chen, Yunzhu Chen, Guo-qing Chen, Miao Chen, Zhi Chen, Junhui Chen, Jing-Xian Chen, Zhiquan Chen, Shuhuang Chen, Shaokang Chen, Irwin Chen, Xiang Chen, Chuo Chen, Siting Chen, Keyuan Chen, Xia-Fei Chen, Zhihai Chen, Yuanyu Chen, Po-Sheng Chen, Qingjiang Chen, Yi-Bing Chen, Rongrong Chen, Katherine C Chen, Shaoxing Chen, Lifen Chen, Luyi Chen, Sisi Chen, Ning-Bo Chen, Yihong Chen, Guanjie Chen, Li-Hua Chen, Xiao-Hui Chen, Ting Chen, Chun-Han Chen, Xuzhuo Chen, Junming Chen, Zheng Chen, Wen-Jie Chen, Bingdi Chen, Jiang Ye Chen, Yanbin Chen, Duoting Chen, Shunyou Chen, Shaohua Chen, Jien-Jiun Chen, Jiaohua Chen, Shaoze Chen, Yifang Chen, Chiqi Chen, Yen-Hao Chen, Rui-Fang Chen, Hung-Sheng Chen, Kuey Chu Chen, Y S Chen, Xijun Chen, Chaoyue Chen, Heng-Sheng Chen, Lianfeng Chen, Yen-Ching Chen, Yuhong Chen, Yixin Chen, Yuanli Chen, Cancan Chen, Yanming Chen, Yajun Chen, Chaoping Chen, F-K Chen, Menglan Chen, Zi-Yang Chen, Yongfang Chen, Hsin-Hong Chen, Hongyan Chen, Chao-Wei Chen, Jijun Chen, Xiaochun Chen, Yazhuo Chen, Zhixin Chen, YongPing Chen, Jui-Yu Chen, Mian-Mian Chen, Liqiang Chen, Y P Chen, D-F Chen, Jinhao Chen, Yanyan Chen, Chang-Zheng Chen, Shao-long Chen, Guoshun Chen, Lo-Yun Chen, Yen-Lin Chen, Bingqian Chen, Dafang Chen, Yi-Chung Chen, Liming Chen, Qiuli Chen, Shuying Chen, Chih-Mei Chen, Renyu Chen, Wei-Hao Chen, Lihua Chen, Hang Chen, Hai-Ning Chen, Hu Chen, Yu-Fu Chen, Yalan Chen, Wan-Tzu Chen, Benjamin Jieming Chen, Yingting Chen, Jiacai Chen, Ning-Yuan Chen, Shuo-Bin Chen, Yu-Ling Chen, Jian-Kang Chen, Hengsan Chen, Yu-Ting Chen, Y Chen, Qingjie Chen, Jiong Chen, Chaoyi Chen, Yunlin Chen, Gang Chen, Hui-Chun Chen, Li-Tzong Chen, Zhangliang Chen, Qiangpu Chen, Xianbo Chen, Jinxuan Chen, Hebing Chen, Ran Chen, Zhehui Chen, Carol X-Q Chen, Yuping Chen, Xiangyu Chen, Xinyu Chen, Qianyun Chen, Junyi Chen, B-S Chen, Zhesheng Chen, Man Chen, Dali Chen, Danyu Chen, Huijiao Chen, Naisong Chen, Qitong Chen, Chueh-Tan Chen, Kai-Ming Chen, Jiarou Chen, Huang Chen, Chunjie Chen, Weiping Chen, Po-Min Chen, Guang-Chao Chen, Danxia Chen, Youran Chen, Chuanzhi Chen, Peng-Cheng Chen, Wen-Tsung Chen, Linxi Chen, Si-guo Chen, Zike Chen, Zhiyu Chen, Wanting Chen, Jiangxia Chen, Wenhua Chen, Roufen Chen, Shi-You Chen, Fang-Pei Chen, Chu Chen, Feifeng Chen, Chunlin Chen, Yunwei Chen, Wenbing Chen, Xuejun Chen, Meizhen Chen, Li Jia Chen, Tianhua Chen, Xiangmei Chen, Kewei Chen, Yuh-Ling Chen, Dejuan Chen, Jiyan Chen, Xinzhuo Chen, Yue-Lai Chen, Hsiao-Jou Cortina Chen, Weiqin Chen, Huey-Miin Chen, Elizabeth Suchi Chen, Kai-Ting Chen, Lizhen Chen, Xiaowen Chen, Chien-Yu Chen, Lingjun Chen, Gonglie Chen, Jiao Chen, Zhuo-Yuan Chen, Wei-Peng Chen, Xiangna Chen, Jiade Chen, Lanmei Chen, Siyu Chen, Kunpeng Chen, Hung-Chi Chen, Jia Chen, Shuwen Chen, Siqin Chen, Zhenlei Chen, Wen-Yi Chen, Si-Yuan Chen, Yidan Chen, Tianfeng Chen, Fu Chen, Leqi Chen, Jiamiao Chen, Shasha Chen, Qingyi Chen, Ben-Kuen Chen, Haitao Chen, Qi Chen, Yihao Chen, Yunfeng Chen, Elizabeth S Chen, Yiming Chen, Youwei Chen, Lichun Chen, Yanfei Chen, Hongxing Chen, Muh-Shy Chen, Yingyu Chen, Weihong Chen, Ming Chen, Kelin Chen, Duan-Yu Chen, Shi-Yi Chen, Shih-Yu Chen, Yanling Chen, Shuanghui Chen, Ya Chen, Yusheng Chen, Yuting Chen, Shiming Chen, Xinqiao Chen, Hongbo Chen, Mien-Cheng Chen, Jiacheng Chen, Herbert Chen, Ji-ling Chen, Sun Chen, Chen-Sheng Chen, Na Chen, Chih-Yi Chen, Wenfang Chen, Yii-Der I Chen, Qinghua Chen, Shuai Chen, Hsi-Hsien Chen, F Chen, Guo-Chong Chen, Zhe Chen, Beijian Chen, Roger Chen, You-Ming Chen, Hongzhi Chen, Zhen-Yu Chen, Xianxiong Chen, Chang Chen, Chujie Chen, Chuannan Chen, Kan Chen, Lu-Biao Chen, Yupei Chen, Qiu-Sheng Chen, Shangduo Chen, Yuan-Yuan Chen, Yundai Chen, Binzhen Chen, Cai-Long Chen, Yen-Chen Chen, Xue-Xin Chen, Yanru Chen, Chunxiu Chen, Yifa Chen, Xingdong Chen, Ruey-Hwa Chen, Shangzhong Chen, Ching-Wen Chen, Danna Chen, Jingjing Chen, Yafei Chen, Dandan Chen, Pei-Yi Chen, Shan Chen, Guanghao Chen, Longqing Chen, Yen-Cheng Chen, Zhanjuan Chen, Jinguo Chen, Zhongxiu Chen, Rui-Min Chen, Shunde Chen, Xun Chen, Jianmin Chen, Linyi Chen, Ying-Ying Chen, Chien-Hsiun Chen, Li-Nan Chen, Yu-Ming Chen, Qianqian Chen, Xue-Yan Chen, Shengdi Chen, Huali Chen, Xinyue Chen, Ching-Yi Chen, Honghai Chen, Baosheng Chen, Pingguo Chen, Yike Chen, Yuxiang Chen, Qing-Hui Chen, Yuanwen Chen, Yongming Chen, Zongzheng Chen, Ruiying Chen, Huafei Chen, Tingen Chen, Zhouliang Chen, Shih-Yin Chen, Shanyuan Chen, Yiyin Chen, Feiyu Chen, Zitao Chen, Constance Chen, Zhoulong Chen, Haide Chen, Jiang Chen, Ray-Jade Chen, Shiuhwei Chen, Chih-Chieh Chen, Chaochao Chen, Qianling Chen, Jian-Min Chen, Xihui Chen, Yuli Chen, Wu-Jun Chen, Diyun Chen, Alice P Chen, Jingxuan Chen, Chiung-Mei Chen, Shibo Chen, M L Chen, Lena W Chen, Xiujuan Chen, Christopher S Chen, Yeh Chen, Xingyong Chen, Feixue Chen, Boyu Chen, Weixian Chen, Tingting Chen, Bosong Chen, Junjie Chen, Han-Min Chen, Szu-Yun Chen, Qingliang Chen, Huatao Chen, Bin Chen, L B Chen, Xuanyi Chen, Chun Chen, Dong Chen, Yinjuan Chen, Jiejian Chen, Lu-Zhu Chen, Alex F Chen, Pei-Chun Chen, Chien-Jen Chen, Y M Chen, Xiao-Chen Chen, Tania Chen, Yang Chen, Yangxin Chen, Mark I-Cheng Chen, Haiming Chen, Shuo Chen, Yong Chen, Hsiao-Tan Chen, Erzhen Chen, Jiaye Chen, Fangyan Chen, Guanzheng Chen, Haoyun Chen, Jiongyu Chen, Baofeng Chen, Yuqin Chen, Juan Chen, Haobo Chen, Shuhong Chen, Fu-Shou Chen, Wei-Yu Chen, Haw-Wen Chen, Feifan Chen, Deqian Chen, Linlin Chen, Xiaoshan Chen, Hui Chen, Wenwen Chen, Yanli Chen, Yuexuan Chen, Xiaoyin Chen, Yen-Chang Chen, Tiantian Chen, Ruiai Chen, Alice Y Chen, Jinglin Chen, Zifan Chen, Wantao Chen, Shanshan Chen, Jianjun Chen, Xiaoyuan Chen, Xuefei Chen, Runfeng Chen, Weisan Chen, Guangnan Chen, Junpan Chen, An Chen, Lankai Chen, Yiding Chen, Tianpeng Chen, Ya-Ting Chen, Lijin Chen, Ching-Yu Chen, Y Eugene Chen, Guanglong Chen, Rongyuan Chen, Yali Chen, Yanan Chen, Liyun Chen, Shuai-Bing Chen, Zhixue Chen, Xiaolu Chen, Xiao-he Chen, Hongxiang Chen, Bing-Feng Chen, Gary K Chen, Xiaohui Chen, Jin-Wu Chen, Qiuxiang Chen, Huaqiu Chen, X Steven Chen, Xiaoqian Chen, Chao-Jung Chen, Zhengjun Chen, Yong-Ping Chen, Zhelin Chen, Xuancai Chen, Yi-Hsuan Chen, Daiyu Chen, Gui Mei Chen, Hongqi Chen, Zhizhong Chen, Mengting Chen, Guofang Chen, Jian-Guo Chen, Hou-Zao Chen, Yuyao Chen, Lixia Chen, Yu-Yang Chen, Zhengling Chen, Qinfen Chen, Jiajun Chen, Xue-Qing Chen, Shenghui Chen, Yii-Derr Chen, Linbo Chen, Yanjing Chen, S Pl Chen, Chi-Long Chen, Jiawei Chen, Rong-Hua Chen, Shu-Fen Chen, Yu-San Chen, Ying-Lan Chen, Xiaofen Chen, Weican Chen, Xin Chen, Yumei Chen, Ruohong Chen, You-Xin Chen, Tse-Ching Chen, Xiancheng Chen, Yu-Pei Chen, Weihao Chen, Baojiu Chen, Haimin Chen, Zhihong Chen, Jion Chen, Yi-Chun Chen, Ping-Kun Chen, Wan Jun Chen, Willian Tzu-Liang Chen, Qingshi Chen, Ren-Hui Chen, Weihua Chen, Hanjing Chen, Guihao Chen, Xiao-Qing Chen, Po-Yu Chen, Liangsheng Chen, Fred K Chen, Haiying Chen, Tzu-Chieh Chen, Wei J Chen, Zhen Chen, Shu Chen, Jie Chen, Chung-Hao Chen, Zi-Qing Chen, Yu-Xia Chen, Weijia Chen, Ming-Han Chen, Yaodong Chen, Yong-Zhong Chen, Jinquan Chen, Haijiao Chen, Tom Wei-Wu Chen, Jingzhou Chen, Ya-Peng Chen, Shiwei Chen, Xiqun Chen, Yingjie Chen, Wenjun Chen, Linjie Chen, Hung-Chun Chen, Xiaoping Chen, Haoran Chen, Qiang Chen, Sy-Jou Chen, Y U Chen, Weineng Chen, Li-hong Chen, Cheng-Fong Chen, Yajing Chen, Song Chen, Qiaoli Chen, Yiru Chen, Guang-Yu Chen, Zhi-bin Chen, Deyu Chen, C Y Chen, Junhong Chen, Yonghui Chen, Chaoli Chen, Syue-Ting Chen, Sufang Chen, I-Chun Chen, Shangsi Chen, Xiao-Wei Chen, Qinsheng Chen, Zhao-Xia Chen, Yun-Yu Chen, Chi-Chien Chen, Wenxing Chen, Meng Chen, Zixin Chen, Jianhui Chen, Yuanyuan Chen, Jiamin Chen, Wei-Wei Chen, Xingyi Chen, Yen-Ni Chen, Danxiang Chen, Po-Ju Chen, Mei-Ru Chen, Ziying Chen, E S Chen, Tailai Chen, Qingyang Chen, Miaomiao Chen, Shuntai Chen, Wei-Lun Chen, Xuanli Chen, Zhengwei Chen, Fengju Chen, Chengwei Chen, Xujia Chen, Faye H Chen, Xiaoxiao Chen, Shengpan Chen, Shin-Yu Chen, Shiyao Chen, Yuan-Shen Chen, Shengzhi Chen, Shaohong Chen, Ching-Jung Chen, Zihao Chen, Kaiquan Chen, Duo-Xue Chen, Xiaochang Chen, Siping Chen, Rongfeng Chen, Jiali Chen, Hsin-Han Chen, Xiaohua Chen, Delong Chen, Wenjie Chen, Huijia Chen, Yunn-Yi Chen, Siyi Chen, Zhengming Chen, Chu-Huang Chen, Zhuchu Chen, Yuanbin Chen, Jinyong Chen, Yunzhong Chen, Pan Chen, Bihong T Chen, Yunyun Chen, Shujuan Chen, M Chen, Mulan Chen, Jiaren Chen, Zechuan Chen, Jian-Qing Chen, Wei-Hui Chen, Lifeng Chen, Geng Chen, Yan-Ming Chen, Zhijian J Chen, Honghui Chen, Wenfan Chen, Zhongbo Chen, Rouxi Chen, Ye-Guang Chen, Zhimin Chen, Tzu-Ting Chen, Xiaolei Chen, Ziyuan Chen, Shilan Chen, Ruiqi Chen, Xiameng Chen, Huijie Chen, Jiankui Chen, Yuhang Chen, Jianzhong Chen, Wen-Qi Chen, Fa Chen, Shu-Jen Chen, Li-Mien Chen, Xing-Lin Chen, Xuxiang Chen, Erbao Chen, Jiaqing Chen, Hsiang-Wen Chen, Jiaxin Chen
articles
Yu-Chieh Lee, Chia-Yu Su, Yuan-Feng Lin +5 more · 2017 · Oncotarget · Impact Journals · added 2026-04-24
Colorectal cancer (CRC) is one of the leading cancers worldwide. Surgery is the main therapeutic modality for stage II CRC. However, the implementation of adjuvant chemotherapy remains controversial a Show more
Colorectal cancer (CRC) is one of the leading cancers worldwide. Surgery is the main therapeutic modality for stage II CRC. However, the implementation of adjuvant chemotherapy remains controversial and is not universally applied so far. In this study, we found that the protein expression of lysosomal acid phosphatase 2 (ACP2) was increased in CRC and that stage II CRC patients with high ACP2 expression showed a poorer outcome than those with low ACP2 expression (p = 0.004). To investigate this discrepancy, we analyzed the relation between ACP2 expression and several clinical cofactors.Among patients who received chemotherapy, those with an high expression of ACP2 showed better survival in both stage II and III CRC than those with low ACP2 expression. In stage II CRC patients, univariate analysis showed ACP2 expression and T stage to be cofactors significantly associated with overall survival (ACP2: p = 0.006; T stage: p = 0.034). Multivariate Cox proportion hazard model analysis also revealed ACP2 to be an independent prognostic factor for overall survival (ACP2: p = 0.006; T stage: p = 0.041). Furthermore, ACP2-knockdown CRC cells showed an increase in chemoresistance to 5-FU treatment and increased proliferation marker in the ACP2 knockdown clone.Taken together, our results suggested that ACP2 is an unfavorable prognostic factor for stage II CRC and may serve as a potential chemotherapy-sensitive marker to help identify a subset of stage II and III CRC patients for whom chemotherapy would improve survival.Highlights1. To the best of our knowledge, the study is the first report to show ACP2 overexpression in human colorectal cancer (CRC) and its association with poor outcome in stage II CRC.2. Patients with stage II and III CRCs with high expression of ACP2 were more sensitive to chemotherapy than those with a low expression.3. ACP2 expression may serve as a marker for CRC patients receiving chemotherapy and help identify the subset of CRC patients who would benefit from chemotherapy. Show less
📄 PDF DOI: 10.18632/oncotarget.14552
ACP2
XiaoYan Guo, Mingrui Lin, Tengfei Shi +2 more · 2017 · The Tohoku journal of experimental medicine · added 2026-04-24
Multiple osteochondromas (MO) is one of the most common benign bone tumors in humans with an autosomal dominant hereditary mode. MO is a genetic heterogeneity disease with variable number and size of Show more
Multiple osteochondromas (MO) is one of the most common benign bone tumors in humans with an autosomal dominant hereditary mode. MO is a genetic heterogeneity disease with variable number and size of osteochondromas, as well as changeable number and location of diseased bones. Mutations in Exostosin-1/Exostosin-2 (EXT1/EXT2) genes are the main molecular basis of MO. EXT1 and EXT2 genes encode exostosin 1 and exostosin 2, respectively, both of which are transmembrane glycosyltransferases that elongate the chains of heparin sulfate (HS) at HS proteoglycans (HSPGs). HSPGs are considered to be involved in regulating the proliferation and differentiation of chondrocytes. Owing to large size of EXT1/EXT2 genes and lack of mutation hotspots, molecular diagnosis of MO is challenging. Here, we applied targeted next-generation sequencing (t-NGS) in mutation screening of EXT1/EXT2 genes for 10 MO patients. The results were compared and validated with Sanger sequencing. Overall, nine mutations identified by t-NGS were confirmed with Sanger sequencing, excluding two variants of false positive, suggesting the reliability of mutation screening by t-NGS. The nine mutations identified by t-NGS include two missense mutations (EXT1: c.1088G>A and c.2120C>T), one splicing mutation (EXT2: c.744-1G>T), and six nonsense mutations (EXT1: c.351C>G, c.1121G>A, and c.1843₁₈₄₆dup; EXT2: c.67C>T, c.561delG, and c.575T>A). In summary, our paper provides the primary data of the application of t-NGS in MO molecular diagnosis, including six newly identified mutations (EXT1: c.1843₁₈₄₆dup, c.1088G>A, c.351C>G, and c.2120C>T and EXT2: c.744-1G>T and c.575T>A), which further enrich the mutation database of MO from the Chinese population. Show less
no PDF DOI: 10.1620/tjem.242.173
EXT1
Gen Li, Huidong Tang, Cheng Wang +4 more · 2017 · Sleep · Oxford University Press · added 2026-04-24
The aim of the study was to investigate the relationship between genetic factors and primary restless legs syndrome (RLS) in Chinese population. A total of 116 RLS patients and 200 controls were recru Show more
The aim of the study was to investigate the relationship between genetic factors and primary restless legs syndrome (RLS) in Chinese population. A total of 116 RLS patients and 200 controls were recruited and the diagnosis of RLS was based on the criteria of International RLS Study Group. Polymer chain reaction (PCR) and sequencing were used to detect 19 single nucleotide polymorphisms (SNPs) in six genetic loci (MEIS1, BTBD9, PTPRD, MAP2K5/SKOR1, TOX3, and Intergenic region of 2p14). Our study found that one SNP increased the risk of RLS in Chinese population: rs6494696 of MAP2K5/SKOR1 (odds ratio [OR] = 0.09, p < .0001, recessive model). A further meta-analysis of RLS in Asian population found that two SNPs of BTBD9 increased the risk of RLS: rs9296249 of BTBD9 (OR = 1.44, p = .000, T allele), rs9357271 of BTBD9 (OR = 1.38, p = .021, dominant model). Our results confirmed the association of BTBD9 and MAP2K5/SKOR1 with primary RLS in Chinese population. Show less
no PDF DOI: 10.1093/sleep/zsx028
MAP2K5
Ting Chen, Lei Lu, Cai Xu +5 more · 2017 · Scientific reports · Nature · added 2026-04-24
With emerging evidence connecting cholesterol dysregulation with disturbed pulmonary homeostasis, we are wondering if diet induced hypercholesterolemia would influence the susceptibility to chemical i Show more
With emerging evidence connecting cholesterol dysregulation with disturbed pulmonary homeostasis, we are wondering if diet induced hypercholesterolemia would influence the susceptibility to chemical induced lung tumorigenesis in mice. Six to eight week-old male C57BL/6J mice were fed with either a high-cholesterol atherogenic diet (HCD) or matching normal diet (ND), respectively. Following 3 weeks diet adapting, a multi-dose intraperitoneal injections of ethyl carbamate (urethane, 1 g/kg body weight) were established and lung tumorigenesis assessments were taken after 15 weeks latency period. Compared to the urethane treated ND-fed mice, the HCD-fed mice exhibited significantly decreased lung tumor multiplicity and attenuated pulmonary inflammation, which including reduced influx of leukocytes and down regulated tumor-promoting cyto-/chemokine profile in bronchoalveolar lavage fluid, decreased TLR2/4 expression and NF-κB activation in the lung. As a sensor regulating intracellular cholesterol homeostasis, nuclear receptor LXR-α was up-regulated significantly in the urethane treated HCD-fed mice lungs compared to the ND-fed mice lungs, accompanied with decreased pulmonary free cholesterol content and suppressed tumor cell proliferation. These results suggested that intrapulmonary cholesterol homeostasis, other than systematic cholesterol level, is important in lung tumorigenesis, and LXR activation might partly contribute to the inhibitory role of atherogenic diet on lung tumorigenesis. Show less
no PDF DOI: 10.1038/s41598-017-05053-1
NR1H3
Pei-Wen Wang, Yu-Ching Hung, Tung-Ho Wu +3 more · 2017 · Oncotarget · Impact Journals · added 2026-04-24
Hepatic fibrosis may ultimately result in organ failure and death, a reality compounded by the fact that most drugs for liver fibrosis appear to be effective only if given as a prophylactic or early t Show more
Hepatic fibrosis may ultimately result in organ failure and death, a reality compounded by the fact that most drugs for liver fibrosis appear to be effective only if given as a prophylactic or early treatment. In a dimethylnitrosamine-induced liver fibrotic model, aspartate aminotransferase/alanine aminotransferase levels could not precisely distinguish the differences between the initial stage of liver fibrosis and normal control, whereas histological examination indicated that dimethylnitrosamine treatment for two weeks has resulted in hepatic fibrogenesis. Comprehensive proteomics identified 12 proteins mainly associated with the interleukin 6-stimulated inflammatory pathway. Coordinately, cytokine profiles showed that dimethylnitrosamine administration would stimulate various signaling pathways leading to liver fibrosis. Of note, apolipoprotein A4 in serum samples obtained from patients in the early stage of liver fibrosis were significantly increased compared to the healthy controls ( Show less
📄 PDF DOI: 10.18632/oncotarget.21627
APOA4
Zhanfei Chen, Nanhong Tang, Xiaoqian Wang +1 more · 2017 · Journal of cellular and molecular medicine · Blackwell Publishing · added 2026-04-24
Carbamoyl phosphate synthase 1 (CPS1) is the rate-limiting enzyme in the first step of the urea cycle and an indispensable enzyme in the metabolism of human liver. However, CPS1 epigenetic regulation Show more
Carbamoyl phosphate synthase 1 (CPS1) is the rate-limiting enzyme in the first step of the urea cycle and an indispensable enzyme in the metabolism of human liver. However, CPS1 epigenetic regulation involves promoter analysis and the role of liver-enriched transcription factors (LETFs), which is not fully elucidated. In this work, the promoter region of hCPS1 gene was cloned, and its activity was investigated. An LETF, hepatocyte nuclear factor 3-beta (HNF3β), was found to promote the transcriptional expression of CPS1 in liver-derived cell lines. In addition, dual-luciferase reporter assay shows that the essential binding sites of the HNF3β may exist in the oligonucleotide -70 nt to +73 nt. Two putative binding sites are available for HNF3β. Mutation analysis results show that the binding site 2 of HNF3β was effective, and the transcriptional activity of CPS1 promoter significantly decreased after mutation. Electrophoretic mobile shift assay (EMSA) and ChIP assay confirmed that HNF3β can interact with the binding site in the CPS1 promoter region of -70 nt to +73 nt promoter region in vivo and in vitro to regulate the transcription of CPS1. Moreover, HNF3β overexpression enhanced the transcription of CPS1 and consequently improved the mRNA and protein levels of CPS1, whereas the knockdown of HNF3β showed the opposite effects. Finally, urea production in cells was measured, and ammonia detoxification improved significantly in cells after transfection with HNF3β. HNF3β plays a vital role in regulation of CPS1 gene and could promote the metabolism of ammonia by regulating CPS1 expression. Show less
📄 PDF DOI: 10.1111/jcmm.13123
CPS1
HPS3/TIMI55–REVEAL Collaborative Group, Louise Bowman, Jemma C Hopewell +9 more · 2017 · The New England journal of medicine · added 2026-04-24
Patients with atherosclerotic vascular disease remain at high risk for cardiovascular events despite effective statin-based treatment of low-density lipoprotein (LDL) cholesterol levels. The inhibitio Show more
Patients with atherosclerotic vascular disease remain at high risk for cardiovascular events despite effective statin-based treatment of low-density lipoprotein (LDL) cholesterol levels. The inhibition of cholesteryl ester transfer protein (CETP) by anacetrapib reduces LDL cholesterol levels and increases high-density lipoprotein (HDL) cholesterol levels. However, trials of other CETP inhibitors have shown neutral or adverse effects on cardiovascular outcomes. We conducted a randomized, double-blind, placebo-controlled trial involving 30,449 adults with atherosclerotic vascular disease who were receiving intensive atorvastatin therapy and who had a mean LDL cholesterol level of 61 mg per deciliter (1.58 mmol per liter), a mean non-HDL cholesterol level of 92 mg per deciliter (2.38 mmol per liter), and a mean HDL cholesterol level of 40 mg per deciliter (1.03 mmol per liter). The patients were assigned to receive either 100 mg of anacetrapib once daily (15,225 patients) or matching placebo (15,224 patients). The primary outcome was the first major coronary event, a composite of coronary death, myocardial infarction, or coronary revascularization. During the median follow-up period of 4.1 years, the primary outcome occurred in significantly fewer patients in the anacetrapib group than in the placebo group (1640 of 15,225 patients [10.8%] vs. 1803 of 15,224 patients [11.8%]; rate ratio, 0.91; 95% confidence interval, 0.85 to 0.97; P=0.004). The relative difference in risk was similar across multiple prespecified subgroups. At the trial midpoint, the mean level of HDL cholesterol was higher by 43 mg per deciliter (1.12 mmol per liter) in the anacetrapib group than in the placebo group (a relative difference of 104%), and the mean level of non-HDL cholesterol was lower by 17 mg per deciliter (0.44 mmol per liter), a relative difference of -18%. There were no significant between-group differences in the risk of death, cancer, or other serious adverse events. Among patients with atherosclerotic vascular disease who were receiving intensive statin therapy, the use of anacetrapib resulted in a lower incidence of major coronary events than the use of placebo. (Funded by Merck and others; Current Controlled Trials number, ISRCTN48678192 ; ClinicalTrials.gov number, NCT01252953 ; and EudraCT number, 2010-023467-18 .). Show less
no PDF DOI: 10.1056/NEJMoa1706444
CETP
Yang An, Shuzhen Wang, Songlin Li +9 more · 2017 · BMC cancer · BioMed Central · added 2026-04-24
Uterine leiomyosarcoma (ULMS) is an aggressive form of soft tissue tumors. The molecular heterogeneity and pathogenesis of ULMS are not well understood. Expression profiling data were used to determin Show more
Uterine leiomyosarcoma (ULMS) is an aggressive form of soft tissue tumors. The molecular heterogeneity and pathogenesis of ULMS are not well understood. Expression profiling data were used to determine the possibility and optimal number of ULMS molecular subtypes. Next, clinicopathological characters and molecular pathways were analyzed in each subtype to prospect the clinical applications and progression mechanisms of ULMS. Two distinct molecular subtypes of ULMS were defined based on different gene expression signatures. Subtype I ULMS recapitulated low-grade ULMS, the gene expression pattern of which resembled normal smooth muscle cells, characterized by overexpression of smooth muscle function genes such as LMOD1, SLMAP, MYLK, MYH11. In contrast, subtype II ULMS recapitulated high-grade ULMS with higher tumor weight and invasion rate, and was characterized by overexpression of genes involved in the pathway of epithelial to mesenchymal transition and tumorigenesis, such as CDK6, MAPK13 and HOXA1. We identified two distinct molecular subtypes of ULMS responding differently to chemotherapy treatment. Our findings provide a better understanding of ULMS intrinsic molecular subtypes, and will potentially facilitate the development of subtype-specific diagnosis biomarkers and therapy strategies for these tumors. Show less
📄 PDF DOI: 10.1186/s12885-017-3568-y
LMOD1
Andrew R Wood, Anna Jonsson, Anne U Jackson +49 more · 2017 · Diabetes · added 2026-04-24
Understanding the physiological mechanisms by which common variants predispose to type 2 diabetes requires large studies with detailed measures of insulin secretion and sensitivity. Here we performed Show more
Understanding the physiological mechanisms by which common variants predispose to type 2 diabetes requires large studies with detailed measures of insulin secretion and sensitivity. Here we performed the largest genome-wide association study of first-phase insulin secretion, as measured by intravenous glucose tolerance tests, using up to 5,567 individuals without diabetes from 10 studies. We aimed to refine the mechanisms of 178 known associations between common variants and glycemic traits and identify new loci. Thirty type 2 diabetes or fasting glucose-raising alleles were associated with a measure of first-phase insulin secretion at Show less
no PDF DOI: 10.2337/db16-1452
VPS13C
Gu Jing, Junqin Chen, Guanlan Xu +1 more · 2016 · Molecular metabolism · Elsevier · added 2026-04-24
Carbohydrate-response element-binding protein (ChREBP) is the major transcription factor conferring glucose-induced gene expression in pancreatic islets, liver and adipose tissue. Recently, a novel Ch Show more
Carbohydrate-response element-binding protein (ChREBP) is the major transcription factor conferring glucose-induced gene expression in pancreatic islets, liver and adipose tissue. Recently, a novel ChREBP isoform, ChREBP-β, was identified in adipose tissue and found to be also expressed in islets and involved in glucose-induced beta cell proliferation. However, the physiological function of this less abundant β-isoform in the islet, and in diabetes, is largely unknown. The aims of the present study, therefore, were to determine how diabetes affects ChREBP-β and elucidate its physiological role in pancreatic beta cells. Non-obese diabetic and obese, diabetic ob/ob mice were used as models of T1D and T2D and human islets and the rat INS-1 beta cell line were exposed to low/high glucose and used for ChREBP isoform-specific gain-and-loss-of-function experiments. Changes in ChREBP-β and ChREBP-α were assessed by qRT-PCR, immunoblotting, promoter luciferase, and chromatin immunoprecipitation studies. Expression of the ChREBP-β isoform was highly induced in diabetes and by glucose, whereas ChREBP-α was downregulated. Interestingly, ChREBP-β gain-of-function experiments further revealed that it was ChREBP-β that downregulated ChREBP-α through a negative feedback loop. On the other hand, ChREBP-β knockdown led to unabated ChREBP-α activity and glucose-induced expression of target genes, suggesting that one of the physiological roles of this novel β-isoform is to help keep glucose-induced and ChREBP-α-mediated gene expression under control. We have identified a previously unappreciated negative feedback loop by which glucose-induced ChREBP-β downregulates ChREBP-α-signaling providing new insight into the physiological role of islet ChREBP-β and into the regulation of glucose-induced gene expression. Show less
📄 PDF DOI: 10.1016/j.molmet.2016.09.010
MLXIPL
Jiping Yue, Yao Zhang, Wenguang G Liang +9 more · 2016 · Nature communications · Nature · added 2026-04-24
Turnover of focal adhesions allows cell retraction, which is essential for cell migration. The mammalian spectraplakin protein, ACF7 (Actin-Crosslinking Factor 7), promotes focal adhesion dynamics by Show more
Turnover of focal adhesions allows cell retraction, which is essential for cell migration. The mammalian spectraplakin protein, ACF7 (Actin-Crosslinking Factor 7), promotes focal adhesion dynamics by targeting of microtubule plus ends towards focal adhesions. However, it remains unclear how the activity of ACF7 is regulated spatiotemporally to achieve focal adhesion-specific guidance of microtubule. To explore the potential mechanisms, we resolve the crystal structure of ACF7's NT (amino-terminal) domain, which mediates F-actin interactions. Structural analysis leads to identification of a key tyrosine residue at the calponin homology (CH) domain of ACF7, whose phosphorylation by Src/FAK (focal adhesion kinase) complex is essential for F-actin binding of ACF7. Using skin epidermis as a model system, we further demonstrate that the phosphorylation of ACF7 plays an indispensable role in focal adhesion dynamics and epidermal migration in vitro and in vivo. Together, our findings provide critical insights into the molecular mechanisms underlying coordinated cytoskeletal dynamics during cell movement. Show less
📄 PDF DOI: 10.1038/ncomms11692
MACF1
Yao Hu, Huaixing Li, Ling Lu +11 more · 2016 · Human molecular genetics · Oxford University Press · added 2026-04-24
Epidemiological studies suggest that levels of n-3 and n-6 long-chain polyunsaturated fatty acids are associated with risk of cardio-metabolic outcomes across different ethnic groups. Recent genome-wi Show more
Epidemiological studies suggest that levels of n-3 and n-6 long-chain polyunsaturated fatty acids are associated with risk of cardio-metabolic outcomes across different ethnic groups. Recent genome-wide association studies in populations of European ancestry have identified several loci associated with plasma and/or erythrocyte polyunsaturated fatty acids. To identify additional novel loci, we carried out a genome-wide association study in two population-based cohorts consisting of 3521 Chinese participants, followed by a trans-ethnic meta-analysis with meta-analysis results from 8962 participants of European ancestry. Four novel loci (MYB, AGPAT4, DGAT2 and PPT2) reached genome-wide significance in the trans-ethnic meta-analysis (log10(Bayes Factor) ≥ 6). Of them, associations of MYB and AGPAT4 with docosatetraenoic acid (log10(Bayes Factor) = 11.5 and 8.69, respectively) also reached genome-wide significance in the Chinese-specific genome-wide association analyses (P = 4.15 × 10(-14) and 4.30 × 10(-12), respectively), while associations of DGAT2 with gamma-linolenic acid (log10(Bayes Factor) = 6.16) and of PPT2 with docosapentaenoic acid (log10(Bayes Factor) = 6.24) were nominally significant in both Chinese- and European-specific genome-wide association analyses (P ≤ 0.003). We also confirmed previously reported loci including FADS1, NTAN1, NRBF2, ELOVL2 and GCKR. Different effect sizes in FADS1 and independent association signals in ELOVL2 were observed. These results provide novel insight into the genetic background of polyunsaturated fatty acids and their differences between Chinese and European populations. Show less
no PDF DOI: 10.1093/hmg/ddw002
FADS1
Yun Ma, Shuai Tian, Shuya He +5 more · 2016 · Gene · Elsevier · added 2026-04-24
The biological effects of microRNAs (miRNAs) in the Fragile X Syndrome (FXS) have been widely studied. Dysregulation of miRNAs plays a critical role in the progression of nervous system diseases and i Show more
The biological effects of microRNAs (miRNAs) in the Fragile X Syndrome (FXS) have been widely studied. Dysregulation of miRNAs plays a critical role in the progression of nervous system diseases and in cell proliferation and differentiation. Our previous study validated that miR-19b-3p was associated with FXR1 (Fragile X related gene 1), one of homologous genes of FMR1 (Fragile X mental retardation 1). The purpose of this study was to investigate the relationship of FXR1 and miR-19b-3p, and the crucial role of miR-19b-3p in FXS and to validate whether miR-19b-3p could regulate the growth of SH-SY5Y cells. We determined that miR-19b-3p could regulate the expression of not only USP32, RAB18 and Dusp6 but also FXR1, and FXR1 could in turn regulate the expression of miR-19b-3p. What's more, the overexpression of miR-19b-3p significantly inhibited the proliferation, contributed the apoptosis and slowed down the cycle of SH-SY5Y cells. Taken together, our results indicate that miR-19b-3p plays a significant role in the molecular pathology of FXS by interacting with FXR1 and influencing the growth of SH-SY5Y cells. Show less
no PDF DOI: 10.1016/j.gene.2016.04.037
DUSP6
Tze-Kiong Er, Yu-Fa Su, Chun-Chieh Wu +9 more · 2016 · Journal of molecular medicine (Berlin, Germany) · Springer · added 2026-04-24
Recent molecular and pathological studies suggest that endometriosis may serve as a precursor of ovarian cancer (endometriosis-associated ovarian cancer, EAOC), especially of the endometrioid and clea Show more
Recent molecular and pathological studies suggest that endometriosis may serve as a precursor of ovarian cancer (endometriosis-associated ovarian cancer, EAOC), especially of the endometrioid and clear cell subtypes. Accordingly, this study had two cardinal aims: first, to obtain mutation profiles of EAOC from Taiwanese patients; and second, to determine whether somatic mutations present in EAOC can be detected in preneoplastic lesions. Formalin-fixed paraffin-embedded (FFPE) tissues were obtained from ten endometriosis patients with malignant transformation. Macrodissection was performed to separate four different types of cells from FFPE sections in six patients. The four types of samples included normal endometrium, ectopic endometriotic lesion, atypical endometriosis, and carcinoma. Ultra-deep (>1000×) targeted sequencing was performed on 409 cancer-related genes to identify pathogenic mutations associated with EAOC. The most frequently mutated genes were PIK3CA (6/10) and ARID1A (5/10). Other recurrently mutated genes included ETS1, MLH1, PRKDC (3/10 each), and AMER1, ARID2, BCL11A, CREBBP, ERBB2, EXT1, FANCD2, MSH6, NF1, NOTCH1, NUMA1, PDE4DIP, PPP2R1A, RNF213, and SYNE1 (2/10 each). Importantly, in five of the six patients, identical somatic mutations were detected in atypical endometriosis and tumor lesions. In two patients, genetic alterations were also detected in ectopic endometriotic lesions, indicating the presence of genetic alterations in preneoplastic lesion. Genetic analysis in preneoplastic lesions may help to identify high-risk patients at early stage of malignant transformation and also shed new light on fundamental aspects of the molecular pathogenesis of EAOC. Molecular characterization of endometriosis-associated ovarian cancer genes by targeted NGS. Candidate genes predictive of malignant transformation were identified. Chromatin remodeling, PI3K-AKT-mTOR, Notch signaling, and Wnt/β-catenin pathway may promote cell malignant transformation. Show less
no PDF DOI: 10.1007/s00109-016-1395-2
EXT1
Xiaochuan Liu, Aoli Wang, Xiaofei Liang +23 more · 2016 · Oncotarget · Impact Journals · added 2026-04-24
PI3Kδ has been found to be over-expressed in B-Cell-related malignancies. Despite the clinical success of the first selective PI3Kδ inhibitor, CAL-101, inhibition of PI3Kδ itself did not show too much Show more
PI3Kδ has been found to be over-expressed in B-Cell-related malignancies. Despite the clinical success of the first selective PI3Kδ inhibitor, CAL-101, inhibition of PI3Kδ itself did not show too much cytotoxic efficacy against cancer cells. One possible reason is that PI3Kδ inhibition induced autophagy that protects the cells from death. Since class III PI3K isoform PIK3C3/Vps34 participates in autophagy initiation and progression, we predicted that a PI3Kδ and Vps34 dual inhibitor might improve the anti-proliferative activity observed for PI3Kδ-targeted inhibitors. We discovered a highly potent ATP-competitive PI3Kδ/Vps34 dual inhibitor, PI3KD/V-IN-01, which displayed 10-1500 fold selectivity over other PI3K isoforms and did not inhibit any other kinases in the kinome. In cells, PI3KD/V-IN-01 showed 30-300 fold selectivity between PI3Kδ and other class I PI3K isoforms. PI3KD/V-IN-01 exhibited better anti-proliferative activity against AML, CLL and Burkitt lymphoma cell lines than known selective PI3Kδ and Vps34 inhibitors. Interestingly, we observed FLT3-ITD AML cells are more sensitive to PI3KD/V-IN-01 than the FLT3 wt expressing cells. In AML cell inoculated xenograft mouse model, PI3KD/V-IN-01 exhibited dose-dependent anti-tumor growth efficacies. These results suggest that dual inhibition of PI3Kδ and Vps34 might be a useful approach to improve the PI3Kδ inhibitor's anti-tumor efficacy. Show less
no PDF DOI: 10.18632/oncotarget.10650
PIK3C3
Jian Meng, Ming Feng, Weibing Dong +11 more · 2016 · Scientific reports · Nature · added 2026-04-24
Transcription factor carbohydrate responsive element binding protein (ChREBP) promotes glycolysis and lipogenesis in metabolic tissues and cancer cells. ChREBP-α and ChREBP-β, two isoforms of ChREBP t Show more
Transcription factor carbohydrate responsive element binding protein (ChREBP) promotes glycolysis and lipogenesis in metabolic tissues and cancer cells. ChREBP-α and ChREBP-β, two isoforms of ChREBP transcribed from different promoters, are both transcriptionally induced by glucose. However, the mechanism by which glucose increases ChREBP mRNA levels remains unclear. Here we report that hepatocyte nuclear factor 4 alpha (HNF-4α) is a key transcription factor for glucose-induced ChREBP-α and ChREBP-β expression. Ectopic HNF-4α expression increased ChREBP transcription while knockdown of HNF-4α greatly reduced ChREBP mRNA levels in liver cancer cells and mouse primary hepatocytes. HNF-4α not only directly bound to an E-box-containing region in intron 12 of the ChREBP gene, but also promoted ChREBP-β transcription by directly binding to two DR1 sites and one E-box-containing site of the ChREBP-β promoter. Moreover, HNF-4α interacted with ChREBP-α and synergistically promoted ChREBP-β transcription. Functionally, HNF-4α suppression reduced glucose-dependent ChREBP induction. Increased nuclear abundance of HNF-4α and its binding to cis-elements of ChREBP gene in response to glucose contributed to glucose-responsive ChREBP transcription. Taken together, our results not only revealed the novel mechanism by which HNF-4α promoted ChREBP transcription in response to glucose, but also demonstrated that ChREBP-α and HNF-4α synergistically increased ChREBP-β transcription. Show less
📄 PDF DOI: 10.1038/srep23944
MLXIPL
Jing Qu, Min Song, Jian Xie +9 more · 2016 · Molecular and cellular biochemistry · Springer · added 2026-04-24
Many studies have explored whether the Notch signaling pathway has a tumor-suppressive or an oncogenic role in various tumors; however, the role of the Notch signaling pathway in salivary adenoid cyst Show more
Many studies have explored whether the Notch signaling pathway has a tumor-suppressive or an oncogenic role in various tumors; however, the role of the Notch signaling pathway in salivary adenoid cystic carcinoma (SACC) is still unknown. In this study, we attempt to define the role of Notch2 signaling in cell growth, invasion, and migration in SACC. We compared Notch2 expression in clinical SACC samples with that of normal samples by using immunohistochemical staining. Then, we down-regulated Notch2 expression to observe the effect of Notch2 on proliferation, invasion, migration, and the expression of known target genes of Notch signal pathway. According to our results, Notch2 expression was higher in SACC tissues compared with normal tissues. Knockdown of Notch2 inhibited cell proliferation, invasion, and migration in vitro and down-regulated the expression of HEY2 and CCND1. The results of this study suggest that Notch2 has an essential role in the cell growth, invasion, and migration of SACC. Notch2 may therefore be a potential target gene for the treatment of SACC by interfering with cell growth and metastasis. Show less
no PDF DOI: 10.1007/s11010-015-2575-z
HEY2
Li-Ting Deng, Yu-Ling Wu, Jun-Cheng Li +8 more · 2016 · PloS one · PLOS · added 2026-04-24
Moringa oleifera is a promising plant species for oil and forage, but its genetic improvement is limited. Our current breeding program in this species focuses on exploiting the functional genes associ Show more
Moringa oleifera is a promising plant species for oil and forage, but its genetic improvement is limited. Our current breeding program in this species focuses on exploiting the functional genes associated with important agronomical traits. Here, we screened reliable reference genes for accurately quantifying the expression of target genes using the technique of real-time quantitative polymerase chain reaction (RT-qPCR) in M. oleifera. Eighteen candidate reference genes were selected from a transcriptome database, and their expression stabilities were examined in 90 samples collected from the pods in different developmental stages, various tissues, and the roots and leaves under different conditions (low or high temperature, sodium chloride (NaCl)- or polyethyleneglycol (PEG)- simulated water stress). Analyses with geNorm, NormFinder and BestKeeper algorithms revealed that the reliable reference genes differed across sample designs and that ribosomal protein L1 (RPL1) and acyl carrier protein 2 (ACP2) were the most suitable reference genes in all tested samples. The experiment results demonstrated the significance of using the properly validated reference genes and suggested the use of more than one reference gene to achieve reliable expression profiles. In addition, we applied three isotypes of the superoxide dismutase (SOD) gene that are associated with plant adaptation to abiotic stress to confirm the efficacy of the validated reference genes under NaCl and PEG water stresses. Our results provide a valuable reference for future studies on identifying important functional genes from their transcriptional expressions via RT-qPCR technique in M. oleifera. Show less
📄 PDF DOI: 10.1371/journal.pone.0159458
ACP2
Chiung-Mei Chen, Yi-Chun Chen, Mu-Chun Chiang +4 more · 2016 · Neurobiology of aging · Elsevier · added 2026-04-24
Recently, a large-scale meta-analysis of genome-wide association study (GWAS) data identified several new risk loci that can modulate the risk of Parkinson's disease (PD). These associations have yet Show more
Recently, a large-scale meta-analysis of genome-wide association study (GWAS) data identified several new risk loci that can modulate the risk of Parkinson's disease (PD). These associations have yet to be examined in PD patients in Chinese or Asian population. Because ethnic-specific effect is an important concern for GWAS analysis, we genotyped single-nucleotide polymorphisms in the new genetic loci, GCH1 (rs11158026), SIPA1L2 (rs10797576), VPS13C (rs2414739), and MIR4697 (rs329648), to investigate their associations with risk of PD in Taiwan. Another single-nucleotide polymorphism GCH1 rs7155501, previously identified by GWAS listed at the top 20 genes in PDGene database was also included. A total of 1151 study subjects comprising 598 patients with PD and 553 unrelated healthy controls were recruited. The frequency of minor allele (C allele) of GCH1 rs11158026 was found to be significantly higher in PD cases than in controls (p = 0.003). The CC genotype of rs11158026 increased PD risk compared to TT genotype (odds ratio [OR] = 1.29, 95% confidence interval [CI] = 1.09, 1.53, p = 0.004). Under additive model, the GCH1 rs11158026 increased the risk of developing PD (OR = 1.30, 95% CI = 1.10, 1.54, p = 0.002). In recessive model, the genotype TT of MIR4697 rs329648 marginally decreased the PD risk (OR = 0.62, 95% CI = 0.43, 0.90, p = 0.01). The PD patients demonstrated similar genotypic and allelic frequencies in GCH1 rs7155501, SIPA1L2 rs10797576, and VPS13C rs2414739 with the controls. These findings suggest that the GCH1 and MIR4697 but not SIPA1L2 and VPS13C are genetic loci influencing risk of PD in Taiwan. Show less
no PDF DOI: 10.1016/j.neurobiolaging.2015.12.016
VPS13C
Qin Zhou, Chi Yang, Min-Jie Chen +1 more · 2016 · Molecular and clinical oncology · added 2026-04-24
Exostosin glycosyltransferase (EXT) 1 and EXT2 have been identified as causative genes in osteochondroma; however, it is not known whether these genes are also involved in condylar osteochondromas. Th Show more
Exostosin glycosyltransferase (EXT) 1 and EXT2 have been identified as causative genes in osteochondroma; however, it is not known whether these genes are also involved in condylar osteochondromas. The aim of this study was to identify EXT1 and EXT2 mutations in patients with non-hereditary osteochondromas of the mandibular condyle. DNA was obtained from resected tissues (cartilage cap) of 12 patients with solitary condylar osteochondromas. The exons, 3',5'-untranslated regions and intron-exon boundaries of EXT1 and EXT2 were amplified by polymerase chain reaction and the products were sequenced directly. Through direct sequencing, four genetic variations of EXT1 in 4 cases and three variations of EXT2 in 5 cases were identified. The intronic alteration of the EXT2 gene, occurring in 2 cases, was novel, whereas the other alterations had been previously reported. Nonsense somatic mutations were detected in tumor DNA. Our study extended the mutational spectrum in EXT1 and EXT2 and may facilitate a better understanding of the pathophysiology of condylar osteochondromas. Show less
no PDF DOI: 10.3892/mco.2016.955
EXT1
Xiao-Qin He, Yue-Qiang Song, Rui Liu +10 more · 2016 · PloS one · PLOS · added 2026-04-24
Axin-1, a negative regulator of Wnt signaling, is a versatile scaffold protein involved in centrosome separation and spindle assembly in mitosis, but its function in mammalian oogenesis remains unknow Show more
Axin-1, a negative regulator of Wnt signaling, is a versatile scaffold protein involved in centrosome separation and spindle assembly in mitosis, but its function in mammalian oogenesis remains unknown. Here we examined the localization and function of Axin-1 during meiotic maturation in mouse oocytes. Immunofluorescence analysis showed that Axin-1 was localized around the spindle. Knockdown of the Axin1 gene by microinjection of specific short interfering (si)RNA into the oocyte cytoplasm resulted in severely defective spindles, misaligned chromosomes, failure of first polar body (PB1) extrusion, and impaired pronuclear formation. However, supplementing the culture medium with the Wnt pathway activator LiCl improved spindle morphology and pronuclear formation. Downregulation of Axin1 gene expression also impaired the spindle pole localization of γ-tubulin/Nek9 and resulted in retention of the spindle assembly checkpoint protein BubR1 at kinetochores after 8.5 h of culture. Our results suggest that Axin-1 is critical for spindle organization and cell cycle progression during meiotic maturation in mouse oocytes. Show less
📄 PDF DOI: 10.1371/journal.pone.0157197
AXIN1
Yan-Bei Yang, Jian-Qing Chen, Yu-Lin Zhao +6 more · 2016 · Frontiers in microbiology · Frontiers · added 2026-04-24
📄 PDF DOI: 10.3389/fmicb.2016.01659
CPS1
Lucas Goedert, Cristiano G Pereira, Jason Roszik +8 more · 2016 · Oncotarget · Impact Journals · added 2026-04-24
Previous work identified RMEL3 as a lncRNA with enriched expression in melanoma. Analysis of The Cancer Genome Atlas (TCGA) data confirmed RMEL3 enriched expression in melanoma and demonstrated its as Show more
Previous work identified RMEL3 as a lncRNA with enriched expression in melanoma. Analysis of The Cancer Genome Atlas (TCGA) data confirmed RMEL3 enriched expression in melanoma and demonstrated its association with the presence of BRAFV600E. RMEL3 siRNA-mediated silencing markedly reduced (95%) colony formation in different BRAFV600E melanoma cell lines. Multiple genes of the MAPK and PI3K pathways found to be correlated with RMEL3 in TCGA samples were experimentally confirmed. RMEL3 knockdown led to downregulation of activators or effectors of these pathways, including FGF2, FGF3, DUSP6, ITGB3 and GNG2. RMEL3 knockdown induces gain of protein levels of tumor suppressor PTEN and the G1/S cyclin-Cdk inhibitors p21 and p27, as well as a decrease of pAKT (T308), BRAF, pRB (S807, S811) and cyclin B1. Consistently, knockdown resulted in an accumulation of cells in G1 phase and subG0/G1 in an asynchronously growing population. Thus, TCGA data and functional experiments demonstrate that RMEL3 is required for MAPK and PI3K signaling, and its knockdown decrease BRAFV600E melanoma cell survival and proliferation. Show less
📄 PDF DOI: 10.18632/oncotarget.9164
DUSP6
Aihui Fan, Qian Wang, Yongjun Yuan +7 more · 2016 · American journal of physiology. Cell physiology · added 2026-04-24
Recent studies have shown that activation of liver X receptors (LXRs) attenuates the development of atherosclerosis, not only by regulating lipid metabolism but also by suppressing inflammatory signal Show more
Recent studies have shown that activation of liver X receptors (LXRs) attenuates the development of atherosclerosis, not only by regulating lipid metabolism but also by suppressing inflammatory signaling. Sphingosine 1-phosphate receptor 2 (S1PR2), an important inflammatory gene product, plays a role in the development of various inflammatory diseases. It was proposed that S1PR2 might be regulated by LXR-α. In the present study, the effect of LXR-α on tumor necrosis factor-α (TNF-α)-induced S1PR2 expression in human umbilical vein endothelial cells (HUVECs) was investigated and the underlying mechanism was explored. The results demonstrated that TNF-α led to an increase in S1PR2 expression and triggered a downregulation of LXR-α expression in HUVECs as well. Downregulation of LXR-α with specific small interfering RNA (siRNA) remarkably enhanced the primary as well as TNF-α-induced expression of S1PR2 in HUVECs. Activation of LXR-α by agonist GW3965 inhibited both primary and TNF-α-induced S1PR2 expression. GW3965 also attenuated S1PR2-induced endothelial barrier dysfunction. The data further showed that TNF-α induced a significant decrease in miR-130a-3p expression. Overexpression of miR-130a-3p with mimic product reduced S1PR2 protein expression, and inhibition of miR-130a-3p by specific inhibitor resulted in an increase in S1PR2 protein expression. Furthermore, activation of LXRs with agonist enhanced the expression of miR-130a-3p, and knockdown of LXR-α by siRNA suppressed miR-130a-3p expression. These results suggest that LXR-α might downregulate S1PR2 expression via miR-130a-3p in quiescent HUVECs. Stimulation of TNF-α attenuates the activity of LXR-α and results in enhanced S1PR2 expression. Show less
no PDF DOI: 10.1152/ajpcell.00102.2015
NR1H3
Daqian Xu, Zheng Wang, Yan Chen · 2016 · Autophagy · Taylor & Francis · added 2026-04-24
As a central node of the macroautophagy/autophagy process, the BECN1/Beclin1-PIK3C3/VPS34 complex participates in different steps of autophagy by interacting with multiple molecules. The ATG14-associa Show more
As a central node of the macroautophagy/autophagy process, the BECN1/Beclin1-PIK3C3/VPS34 complex participates in different steps of autophagy by interacting with multiple molecules. The ATG14-associated PIK3C3 complex is involved in autophagy initiation, whereas the UVRAG-associated complex mainly modulates autophagosome maturation and endosome fusion. However, the molecular mechanism that coordinates the sequential execution of the autophagy program remains unknown. We have recently discovered that a Golgi-resident protein, PAQR3, regulates autophagy initiation as it preferentially facilitates the formation of the ATG14-linked PIK3C3 complex instead of the UVRAG-associated complex. Upon glucose starvation, AMPK directly phosphorylates T32 of PAQR3, which is crucial for the activation of the ATG14-associated class III PtdIns3K. Furthermore, Paqr3-deleted mice have a deficiency in exercise-induced autophagy as well as behavioral disorders. Thus, this work not only uncovers the regulatory mechanism of PAQR3 on autophagy initiation, but also provides a potential candidate therapeutic target for neurodegenerative diseases. Show less
no PDF DOI: 10.1080/15548627.2016.1163459
PIK3C3
Jue Wang, Zhizhong Ye, Shuhui Zheng +4 more · 2016 · Brain research · Elsevier · added 2026-04-24
Determination of the exogenous factors that regulate differentiation of neural stem/progenitor cells into neurons, oligodendrocytes and astrocytes is an important step in the clinical therapy of spina Show more
Determination of the exogenous factors that regulate differentiation of neural stem/progenitor cells into neurons, oligodendrocytes and astrocytes is an important step in the clinical therapy of spinal cord injury (SCI). The Notch pathway inhibits the differentiation of neural stem/progenitor cells and Lingo-1 is a strong negative regulator for myelination and axon growth. While Lingo-1 shRNA and N-[N-(3, 5-difluorophenacetyl)-1-alanyl]-S-Phenylglycinet-butylester (DAPT), a Notch pathway inhibitor, have been used separately to help repair SCI, the results have been unsatisfactory. Here we investigated and elucidated the preliminary mechanism for the effect of Lingo-1 shRNA and DAPT on neural stem/progenitor cells differentiation. We found that neural stem/progenitor cells from E14 rat embryos expressed Nestin, Sox-2 and Lingo-1, and we optimized the transduction of neural stem/progenitor cells using lentiviral vectors encoding Lingo-1 shRNA. The addition of DAPT decreased the expression of Notch intracellular domain (NICD) as well as the downstream genes Hes1 and Hes5. Expression of NeuN, CNPase and GFAP in DAPT treated cells and expression of NeuN in Lingo-1 shRNA treated cells confirmed differentiation of neural stem/progenitor cells into neurons, oligodendrocytes and astrocytes. These results revealed that while Lingo-1 shRNA and Notch signaling inhibitor DAPT both promoted differentiation of neural stem cells into neurons, only DAPT was capable of driving neural stem/progenitor cells differentiation into oligodendrocytes and astrocytes. Since we were able to show that both Lingo-1 shRNA and DAPT could drive neural stem/progenitor cells differentiation, our data might aid the development of more effective SCI therapies using Lingo-1 shRNA and DAPT. Show less
no PDF DOI: 10.1016/j.brainres.2015.11.029
LINGO1
Junxiong Pang, Anna Lindblom, Thomas Tolfvenstam +8 more · 2016 · PloS one · PLOS · added 2026-04-24
Dengue results in a significant public health burden in endemic regions. The World Health Organization (WHO) recommended the use of warning signs (WS) to stratify patients at risk of severe dengue dis Show more
Dengue results in a significant public health burden in endemic regions. The World Health Organization (WHO) recommended the use of warning signs (WS) to stratify patients at risk of severe dengue disease in 2009. However, WS is limited in stratifying adult dengue patients at early infection (Day 1-3 post fever), who require close monitoring in hospitals to prevent severe dengue. The aim of this study is to identify and validate prognostic models, built with differentially expressed biomarkers, that enable the early identification of those with early dengue infection that require close clinical monitoring. RNA microarray and protein assays were performed to identify differentially expressed biomarkers of severity among 92 adult dengue patients recruited at early infection from years 2005-2008. This comprised 47 cases who developed WS after first presentation and required hospitalization (WS+Hosp), as well as 45 controls who did not develop WS after first presentation and did not require hospitalization (Non-WS+Non-Hosp). Independent validation was conducted with 80 adult dengue patients recruited from years 2009-2012. Prognostic models were developed based on forward stepwise and backward elimination estimation, using multiple logistic regressions. Prognostic power was estimated by the area under the receiver operating characteristic curve (AUC). The WS+Hosp group had significantly higher viral load (P<0.001), lower platelet (P<0.001) and lymphocytes counts (P = 0.004) at early infection compared to the Non-WS+Non-Hosp group. From the RNA microarray and protein assays, the top single RNA and protein prognostic models at early infection were CCL8 RNA (AUC:0.73) and IP-10 protein (AUC:0.74), respectively. The model with CCL8, VPS13C RNA, uPAR protein, and with CCL8, VPS13C RNA and platelets were the best biomarker models for stratifying adult dengue patients at early infection, with sensitivity and specificity up to 83% and 84%, respectively. These results were tested in the independent validation group, showing sensitivity and specificity up to 96% and 54.6%, respectively. At early infection, adult dengue patients who later presented WS and require hospitalization have significantly different pathophysiology compared with patients who consistently presented no WS and / or require no hospitalization. The molecular prognostic models developed and validated here based on these pathophysiology differences, could offer earlier and complementary indicators to the clinical WHO 2009 WS guide, in order to triage adult dengue patients at early infection. Show less
no PDF DOI: 10.1371/journal.pone.0155993
VPS13C
Nan Zhu, Mo Chen, Rowena Eng +13 more · 2016 · The Journal of clinical investigation · added 2026-04-24
Self-renewal is a hallmark of both hematopoietic stem cells (HSCs) and leukemia stem cells (LSCs); therefore, the identification of mechanisms that are required for LSC, but not HSC, function could pr Show more
Self-renewal is a hallmark of both hematopoietic stem cells (HSCs) and leukemia stem cells (LSCs); therefore, the identification of mechanisms that are required for LSC, but not HSC, function could provide therapeutic opportunities that are more effective and less toxic than current treatments. Here, we employed an in vivo shRNA screen and identified jumonji domain-containing protein JMJD1C as an important driver of MLL-AF9 leukemia. Using a conditional mouse model, we showed that loss of JMJD1C substantially decreased LSC frequency and caused differentiation of MLL-AF9- and homeobox A9-driven (HOXA9-driven) leukemias. We determined that JMJD1C directly interacts with HOXA9 and modulates a HOXA9-controlled gene-expression program. In contrast, loss of JMJD1C led to only minor defects in blood homeostasis and modest effects on HSC self-renewal. Together, these data establish JMJD1C as an important mediator of MLL-AF9- and HOXA9-driven LSC function that is largely dispensable for HSC function. Show less
no PDF DOI: 10.1172/JCI82978
JMJD1C
Juliet D French, Sharon E Johnatty, Yi Lu +75 more · 2016 · Oncotarget · Impact Journals · added 2026-04-24
Women with epithelial ovarian cancer (EOC) are usually treated with platinum/taxane therapy after cytoreductive surgery but there is considerable inter-individual variation in response. To identify ge Show more
Women with epithelial ovarian cancer (EOC) are usually treated with platinum/taxane therapy after cytoreductive surgery but there is considerable inter-individual variation in response. To identify germline single-nucleotide polymorphisms (SNPs) that contribute to variations in individual responses to chemotherapy, we carried out a multi-phase genome-wide association study (GWAS) in 1,244 women diagnosed with serous EOC who were treated with the same first-line chemotherapy, carboplatin and paclitaxel. We identified two SNPs (rs7874043 and rs72700653) in TTC39B (best P=7x10-5, HR=1.90, for rs7874043) associated with progression-free survival (PFS). Functional analyses show that both SNPs lie in a putative regulatory element (PRE) that physically interacts with the promoters of PSIP1, CCDC171 and an alternative promoter of TTC39B. The C allele of rs7874043 is associated with poor PFS and showed increased binding of the Sp1 transcription factor, which is critical for chromatin interactions with PSIP1. Silencing of PSIP1 significantly impaired DNA damage-induced Rad51 nuclear foci and reduced cell viability in ovarian cancer lines. PSIP1 (PC4 and SFRS1 Interacting Protein 1) is known to protect cells from stress-induced apoptosis, and high expression is associated with poor PFS in EOC patients. We therefore suggest that the minor allele of rs7874043 confers poor PFS by increasing PSIP1 expression. Show less
📄 PDF DOI: 10.18632/oncotarget.7047
CCDC171
Wen-li Song, Yu Tian, Xian-e Wang +7 more · 2016 · Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · added 2026-04-24
To investigate the potential association between FADS1 rs174537 polymorphism and serum proteins in patients with aggressive periodontitis, which may provide benefits for diagnosis and treatment of agg Show more
To investigate the potential association between FADS1 rs174537 polymorphism and serum proteins in patients with aggressive periodontitis, which may provide benefits for diagnosis and treatment of aggressive periodontitis. A total of 353 patients with aggressive periodontitis (group AgP) and 125 matched controls (group HP) were recruited in the study. Genotyping of FADS1 rs174537 and serum biochemical indexes were tested at the study's start. The relationships between the levels of TP, GLB, ALB, A/G and genotyping were analyzed. (1) The detection rate of allele G in group AgP was higher than that in group HP(68.1% vs. 61.2%, P=0.046,OR=1.35,95% CI 1.00-1.83); the detection rate of genotype GG in group AgP was higher than in group HP(45.5% vs. 34.4%,P=0.029, OR=1.60, 95% CI 1.05-2.44). (2) In group AgP, the patients with GG genotype exhibited significantly lower TP, GLB than the patients with GT+TT genotype [(77.08 ± 7.88) g/L vs. (79.00 ± 4.66) g/L, P=0.007; (28.17 ± 7.63) g/L vs.(29.88 ± 3.49) g/L,P=0.007) and the higher A/G(1.72 ± 0.22 vs.1.67 ± 0.22, P=0.040), but there was no significant difference in ALB between the patients with GG genotype and the patients with GT+TT genotype. In group HP, there were no significant differences in TP, GLB, A/G and ALB between individuals with genotype GT+TT and with genotype GG. (3)Compared with individuals with genotype GT+TT in group HP, the AgP patients with genotype GT+TT exhibited significantly higher TP, GLB [(79.00 ± 4.66) g/L vs. (75.20 ± 4.53) g/L, P<0.01; (29.88 ± 3.49) g/L vs.(26.55 ± 2.94) g/L, P<0.01) and the lower A/G(1.67 ± 0.22 vs. 1.88 ± 0.30, P<0.01), but there was no significant difference in ALB. There were no significant differences in TP, GLB, A/G and ALB the between the AgP patients with genotype GG and the healthy subjects with the same genotype either. FADS1 rs174537 polymorphism is associated with aggressive periodontitis. The patients with genotype GG in group AgP had relatively lower TP,GLB and higher A/G. Genotype GG might be a risk indicator for aggressive periodontitis by reducing host defense capability and contributing to inflammatory response in the occurrence and development of aggressive periodontitis. Show less
no PDF
FADS1